Diversity of PEGylation methods of liposomes and their influence on RNA delivery

Nosova, A S; Koloskova, Olesya O.; Nikonova, Alexandra; Simonova, V. A.; Смирнов, В. В.; Kudlаy, D.А.; Khaitov, Musa

doi:10.1039/c8md00515j

Cited by 96 publications

(69 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, liposomes that are more susceptible to break down form micelles and result in faster drug release. In the present study, the prepared PTX/SLP@mPEG with optimally suitable mPEG‐Chol (4%) was used to evaluate the drug release behavior of SLP@mPEG 47 . Figure 7 shows accumulated percent release of free PTX and PTX from SLP@mPEG in PBS (pH 7.4).…”

Section: Resultsmentioning

confidence: 99%

Methoxy polyethylene glycol–cholesterol modified soy lecithin liposomes for poorlywater‐solubleanticancer drug delivery

Nguyen

et al. 2020

J of Applied Polymer Sci

View full text Add to dashboard Cite

Soy lecithin liposomes (SLP) were prepared and partially surface modified with methoxy polyethylene glycol‐cholesterol conjugate (mPEG‐Chol) to improve its poorly‐soluble‐water‐anticancer‐drugs delivery efficiency. Paclitaxel (PTX) was used as the model drug and the PTX/SLP@mPEG was successfully developed with the optimal mass ratio of mPEG‐Chol determined at 4% in the SLP@mPEG formulation. The optimal SLP@mPEG formulation had a particle size range of 161.80 ± 1.51 nm and a negative surface charge of −54.30 ± 1.40 mV. Besides, a sustained drug release profile of 72 h and an encapsulation efficiency of 87.48 ± 0.70% was recorded. Moreover, in vitro cytotoxicity assays demonstrated that SLP@mPEG is nontoxic and cytocompatible. Overall, these obtained results provide insights into the potential of SLP@mPEG as a platform for the development of more effective therapies against cancers.

show abstract

Section: Resultsmentioning

confidence: 99%

Methoxy polyethylene glycol–cholesterol modified soy lecithin liposomes for poorlywater‐solubleanticancer drug delivery

Nguyen

et al. 2020

J of Applied Polymer Sci

View full text Add to dashboard Cite

show abstract

“…High expression levels of both the vimentin and paxillin have been found to significantly contribute both to the malignancy and drug-resistance of CRC [ 47 , 48 , 49 ]. Consequently, the downregulation of the expression levels of the two proteins was found to be related to a reduction of metastatic development [ 50 , 51 , 52 , 53 ]. The investigation proved the time-dependent reduction in the fluorescence intensity of the vimentin and phospho-paxillin, confirming the effective activity of 5-FU on the inhibition of CRC cell proliferation [ 54 ].…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of a Controlled 5-FU Delivery Based on FZD10 Antibody-Conjugated Liposomes in Colorectal Cancer In vitro Models

et al. 2020

View full text Add to dashboard Cite

The use of controlled delivery therapy in colorectal cancer (CRC) reduces toxicity and side effects. Recently, we have suggested that the Frizzled 10 (FZD10) protein, a cell surface receptor belonging to the FZD protein family that is overexpressed in CRC cells, is a novel candidate for targeting and treatment of CRC. Here, the anticancer effect of novel immuno-liposomes loaded with 5-Fluorouracil (5-FU), decorated with an antibody against FZD10 (anti-FZD10/5-FU/LPs), was evaluated in vitro on two different CRC cell lines, namely metastatic CoLo-205 and nonmetastatic CaCo-2 cells, that were found to overexpress FZD10. The anti-FZD10/5-FU/LPs obtained were extensively characterized and their preclinical therapeutic efficacy was evaluated with the MTS cell proliferation assay based on reduction of tetrazolium compound, scratch test, Field Emission Scanning Electron Microscopes (FE-SEM) investigation and immunofluorescence analysis. The results highlighted that the cytotoxic activity of 5-FU was enhanced when encapsulated in the anti-FZD10 /5-FU/LPs at the lowest tested concentrations, as compared to the free 5-FU counterparts. The immuno-liposomes proposed herein possess a great potential for selective treatment of CRC because, in future clinical applications, they can be encapsulated in gastro-resistant capsules or suppositories for oral or rectal delivery, thereby successfully reaching the intestinal tract in a minimally invasive manner.

show abstract

“…The conjugation of fab' fragments with PEG-DSPE-Mal on the surface of targeted liposomes had shown greater targeting ability than the non-pegylated immunoliposomes. [46][47][48] Noticeably the addition of maleimide-terminated linkers for the conjugation of ligands in the pegylated stealth liposomes provides spacer arm for improved binding and internalization. The attachment of targeting moieties at distal end of PEG also support to minimize the steric hindrances by neighboring polymer chain.…”

Section: Discussionmentioning

confidence: 99%

<p>Fatty Acid Synthase (FASN) siRNA-Encapsulated-Her-2 Targeted Fab’-Immunoliposomes for Gene Silencing in Breast Cancer Cells</p>

Khan¹,

Aljarbou²,

Aldebasi³

et al. 2020

IJN

View full text Add to dashboard Cite

The overexpression of Her-2 in 25-30% breast cancer cases and the crosstalk between Her-2 and fatty acid synthase (FASN) establishes Her-2 as a promising target for site-directed delivery. The present study aimed to develop the novel lipid base formulations to target and inhibit the cellular proliferation of Her-2-expressing breast cancer cells through the silencing of FASN. In order to achieve this goal, we prepared DSPC/Chol and DOPE/ CHEMS immunoliposomes, conjugated with the anti-Her-2 fab' and encapsulated FASN siRNA against breast cancer cells. Methods: We evaluated the size, stability, cellular uptake and internalization of various formulations of liposomes. The antiproliferative gene silencing potential was investigated by the cell cytotoxicity, crystal violet, wound healing and Western blot analyses in Her-2 + and Her-2¯breast cancer cells. Results: The data revealed that both nanosized FASN-siRNA-encapsulated liposomes showed significantly higher cellular uptake and internalization with enhanced stability. The cell viability of Her-2 + SK-BR3 cells treated with the targeted formulation of DSPC/Choland DOPE/CHEMS-encapsulating FASN-siRNA reduced to 30% and 20%, respectively, whereas it was found to be 45% and 36% in MCF-7 cells. The wounds were not only failed to close but they became broader in Her-2 + cells treated with targeted liposomes of siRNA. Consequently, the amount of FASN decreased by 80% in SK-BR3 cells treated with nontargeted liposomes and it was 30% and 60% in the MCF-7 cells treated with DSPC/Chol and DOPE/CHEMS liposomes, respectively. Conclusion: In this study, we developed the formulation that targeted Her-2 for the suppression of FASN and, therefore, inhibited the proliferation of breast cancer cells.

show abstract

Diversity of PEGylation methods of liposomes and their influence on RNA delivery

Abstract: A brief review and comparison of the methods of PEGylation of liposomal particles and their influence on the delivery of RNA.

Cited by 96 publications

References 74 publications

Methoxy polyethylene glycol–cholesterol modified soy lecithin liposomes for poorlywater‐solubleanticancer drug delivery

Methoxy polyethylene glycol–cholesterol modified soy lecithin liposomes for poorlywater‐solubleanticancer drug delivery

Effectiveness of a Controlled 5-FU Delivery Based on FZD10 Antibody-Conjugated Liposomes in Colorectal Cancer In vitro Models

<p>Fatty Acid Synthase (FASN) siRNA-Encapsulated-Her-2 Targeted Fab’-Immunoliposomes for Gene Silencing in Breast Cancer Cells</p>

Contact Info

Product

Resources

About